Professional
Added to YB: 2024-12-13
Pitch date: 2024-09-30
PHAT [bullish]
Phathom Pharmaceuticals, Inc.
-52.25%
current return
Author Info
No bio for this author
Company Info
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
Market Cap
$734.7M
Pitch Price
$18.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-34.26
P/E
-7.31
EV/Sales
4.61
Sector
Pharmaceuticals
Category
growth
PGIM Jennison Health Sciences Fund Portfolio Holding: Phathom Pharmaceuticals, Inc.
PHAT: Vonoprazan (Voquezna) for GERD, 1st new mechanism in 30+ yrs. Approved Nov '23 for erosive GERD, recently for non-erosive. Strong launch: robust payer coverage, FDA approval for larger NERD population, positive patient/physician feedback. Early stage, consensus underestimates potential.
Read full article (1 min)